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Abstract
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by impaired antimi-
crobial activity in phagocytic cells. As a monogenic disease affecting the hematopoietic system, CGD is
amenable to gene therapy. Indeed in a phase I/II clinical trial, we demonstrated a transient resolution of
bacterial and fungal infections. However, the therapeutic benefit was compromised by the occurrence of clonal
dominance and malignant transformation demanding alternative vectors with equal efficacy but safety-im-
proved features. In this work we have developed and tested a self-inactivating (SIN) gammaretroviral vector
(SINfes.gp91s) containing a codon-optimized transgene (gp91phox) under the transcriptional control of a
myeloid promoter for the gene therapy of the X-linked form of CGD (X-CGD). Gene-corrected cells protected
X-CGD mice from Aspergillus fumigatus challenge at low vector copy numbers. Moreover, the SINfes.gp91s
vector generates substantial amounts of superoxide in human cells transplanted into immunodeficient mice. In
vitro genotoxicity assays and longitudinal high-throughput integration site analysis in transplanted mice
comprising primary and secondary animals for 11 months revealed a safe integration site profile with no signs
of clonal dominance.
Introduction
Gene therapy of inherited diseases has providedconvincing evidence of therapeutic benefits for many
treated patients. In particular, treatment of primary severe
congenital immunodeficiencies by gene transfer into hemato-
poietic stem cells has proven in some cases to be as beneficial
as allogeneic stem cell transplantation, the treatment of choice
for these diseases if human leukocyte antigen-matched do-
nors are available [reviewed in (Booth et al., 2011; Fischer et al.,
2011; Naldini, 2011; Aiuti et al., 2012; Rivat et al., 2012; Sey-
mour and Thrasher, 2012)]. However, sustained therapeutic
success has been hampered by serious adverse events occur-
ring in a few of the treated patients as a consequence of vector
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integration and activation of proto-oncogenes leading to the
development of myeloproliferative diseases and leukemias
(Hacein-Bey-Abina et al., 2008; Howe et al., 2008; Stein et al.,
2010; Aiuti et al., 2012; Cavazzana-Calvo et al., 2012). Despite
these adverse effects, most patients responded to chemo-
therapy treatment, are currently in complete remission, and
still do contain gene-marked cells that have contributed to the
recovery of immune functions. Three patients (two with the
X-linked form of chronic granulomatous disease [X-CGD] and
one with SCID-X1) succumbed as a consequence of insertion-
mutagenesis-driven leukemia (Rivat et al., 2012).
Previously, we conducted a phase I clinical trial aimed at
the correction of X-CGD, a rare inherited immunodeficiency
characterized by severe and life-threatening bacterial and
fungal infections as well as widespread tissue granuloma
formation. Phagocytic cells of CGD patients fail to kill in-
gested microbes because of a defect in the nicotinamide di-
nucleotide phosphate (NADPH) oxidase complex resulting
in compromised antimicrobial activity (Segal, 1996; Segal
et al., 2000; Holland, 2010). In this clinical trial, we used a
gammaretroviral vector with strong enhancer–promoter se-
quences in the long terminal repeats (LTRs) to genetically
modify CD34+ cells in two X-CGD patients. After successful
reconstitution of phagocytic functions, both patients experi-
enced a clonal outgrowth of gene-marked cells caused by
vector-mediated insertional activation of the EVI1, PRDM16,
and SETBP1 proto-oncogenes leading to the development of
myeloid malignancies in both patients (Ott et al., 2006; Stein
et al., 2010). Moreover, functional correction of gene-transduced
cells decreased with time because of epigenetic inactivation of
the vector promoter within the LTR, resulting in the accumu-
lation of nonfunctional gene-transduced cells (Stein et al., 2010).
A similar expansion of gene-transduced cells with activated
EVI1 was observed in two patients treated at the Children’s
Hospital in Zurich. Both patients underwent allogeneic bone
marrow (BM) transplantation before or at the onset of myelo-
dysplasia and are currently in complete remission (R. Seger
and J. Reichenbach, personal communication).
The understanding of the molecular basis of insertional
mutagenesis after gene therapy has motivated the develop-
ment of advanced integrating vectors with equal therapeutic
potency but reduced genotoxicity (Baum et al., 2004; Naldini,
2011). In our clinical study, insertional oncogenesis was
initiated either by enhancer-mediated activation of proto-
oncogene promoters or by aberrant splicing of transcripts
initiated at the LTR and spliced out into exons of proto-
oncogenes (Ott et al., 2006; Stein et al., 2010). Similarly, LTR-
driven activation of LMO2was identified as the major cause of
lymphoid leukemia after gene therapy of X-linked severe
combined immunodeficiency syndrome (X1-SCID (Hacein-
Bey-Abina et al., 2008; Howe et al., 2008). Therefore, the re-
design of vector architecture has been a matter of intense
work during the past years (Corrigan-Curay et al., 2012). In
particular, the deletion of the enhancer elements within the
viral LTR unique 3¢ (U3) regions has significantly contrib-
uted to the reduction of genotoxic effects associated with
LTR-driven gammaretroviral vectors. Despite their inte-
gration preference in proximity to cellular promoter re-
gions, these U3-deleted self-inactivating (SIN) vectors have
shown an improved safety profile in vitro and in vivo
(Modlich et al., 2006; Montini et al., 2006, 2009). SIN vector
safety can be further improved by the careful selection of
internal promoters to drive transgene expression (Zychlinski
et al., 2008). Accordingly, the use of tissue-specific promoters,
which are inactive in stem/progenitor cells but active in ter-
minally differentiated cells, should further increase the safety
level of SIN vectors (Modlich et al., 2009). Indeed, SIN gam-
maretroviral and lentiviral vectors have shown promising re-
sults in terms of efficacy and safety in several preclinical studies
(Thornhill et al., 2008; Zhou et al., 2010; Avedillo Diez et al.,
2011; Huston et al., 2011; Tolar et al., 2012; Scaramuzza et al.,
2013) and ongoing clinical trials, although the follow-up time of
treated patients is still too short to make conclusive statements
at present (Cartier et al., 2009; Cavazzana-Calvo et al., 2010; Biffi
et al., 2011). On the basis of the aforementioned advancements,
we developed a SIN gammaretroviral vector for the safe and
effective gene therapy of X-linked CGD (SINfes.gp91s). We
combined the SIN configuration with an internal promoter,
with preferential expression in myeloid cells. However, the
introduction of a new vector into the clinic demands a series of
sophisticated preclinical studies that are quite challenging in
particular within an academic environment (Will et al., 2007).
Here, we report on the comprehensive and thorough preclini-
cal efficacy and safety testing of the SINfes.gp91s retroviral
vector assessing dosage requirements, therapeutic efficacy, re-
sistance to transgene silencing, and genotoxic potential.
Results and Discussion
A SIN gammaretroviral vector for X-CGD gene therapy
We designed a new gammaretroviral vector for the gene
therapy of X-CGD based on an advanced SIN vector plat-
form with the following important features: (1) all retroviral
coding sequences are deleted, (2) a primer-binding-site se-
quence is used that escapes targeting by epigenetic silencers
recognizing conventional murine gammaretroviral se-
quences, and (3) modifications of the 5¢ promoter of the
retroviral vector plasmid in combination with a safety-
modified version of the woodchuck hepatitis virus post-
transcriptional regulatory element support production at
high titers (Schambach et al., 2006, 2009). The backbone used
for the construction of SINfes.gp91s was derived from the
SERS11 vector backbone described by Schambach et al.
(2006) containing an internal therapeutic cassette consisting
of a 507 bp DNA fragment derived from the promoter region
of the human c-FES gene driving the expression of a synthetic,
codon-optimized gp91phox cDNA (Moreno-Carranza et al.,
2009). Similar vectors containing either the elongation factor
short promoter or the migration inhibitory factor-related
protein 8 promoter were constructed in parallel and tested for
gp91phox expression and reconstitution of superoxide activity
in vitro and in vivo. Although all vectors performed similarly,
the SINfes.gp91s vector was selected for preclinical studies
based on slightly higher levels of gp91phox expression and
reconstituted NADPH oxidase activity per vector copy num-
ber (VCN) in granulocytes derived from transplanted X-CGD
mice (Supplementary Fig. S1; Supplementary Data are avail-
able online at www.liebertonline.com/humc).
Pharmacodynamic studies: correction of the X-CGD
phenotype by low VCNs in vitro and in vivo
To determine the gene dosage required for an effective
therapeutic effect, we first assessed reconstitution of superoxide
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activity in gene-corrected X-CGD granulocytes in vitro and
in vivo. We tested the performance of SINfes.gp91s in vivo
using male/female or CD45.2/CD45.1 animals to distin-
guish donor from recipient cells. Therefore, we trans-
planted SINfes.gp91s-modifed X-CGD cells differing in the
mean VCN per cell in X-CGD mice, resulting in two cohorts
with low and high VCNs, respectively. In the low-VCN
group, a total of 8 primary and 10 secondary animals (mean
VCN 0.42) were analyzed, whereas the high-VCN group
consisted of 9 primary and 10 secondary transplanted an-
imals (mean VCN 2.9). Engraftment of donor cells was
similar in both groups as assessed by quantitative poly-
merase chain reaction (qPCR) using specific primers for
the murine SRY gene (transplantation of male X-CGD cells
into female X-CGD recipients) or by fluorescence-activated
cell sorting analysis of CD45.2 X-CGD cells engrafted
into CD45.1 recipients. Independently of the setting used,
donor cell engraftment ranged between 80% and 100% in
all animals.
Gp91phox expression was measured by flow cytometry 18–
19 weeks after transplantation in the peripheral blood cells of
treated mice. Gp91phox expression was found on average in
27.1% – 7.7% of the peripheral blood cells in primary and
25.2% – 16.7% in secondary animals in the low-VCN group,
whereas in peripheral blood cells from the high-VCN group
gp91phox expression was on average 64.7% – 23.2% and
56.7% – 23.3% in primary and secondary animals, respec-
tively (Fig. 1A and B, and Supplementary Fig. S2A and B,
p < 0.003 between low- and high-VCN groups). Rescue of
the CGD phenotype was tested by assessing superoxide
production in gene-modified granulocytes using the dihy-
drorhodamine-123 (DHR) assay (Bohler et al., 1986). Super-
oxide production in granulocytes of primary animals ranged
between 17.1% and 70.3% of wild-type (wt) levels (low-VCN
animals) and between 44.6% and 97.8% in the high-VCN
animals (Fig. 1A and Supplementary Fig. S2C and D). In
secondary animals, rhodamine-123-positive granulocytes
ranged between 15.9% and 41.8% in the low-VCN group
and between 27.0% and 93.5% in the high-VCN animals,
respectively (Fig. 1B and Supplementary Fig. S2C, p < 0.0001,
between low- and high-VCN groups). Thus, even at low
VCNs (mean 0.42) gp91phox expression and reconstitution
of superoxide activity at therapeutic relevant levels were
achieved in primary and secondary animals, respectively.
The performance of the SINfes.gp91s vector was also as-
sessed in human hematopoietic cells from X-CGD patients.
For these studies, a pre-GMP vector preparation was used (see
Supplementary Materials and Methods for details). Trans-
duction efficiency into X-CGD CD34+ cells was 28.7%– 8.5%
as estimated from gp91phox expression at a mean VCN of
0.58– 0.11. After transduction, X-CGD CD34+ cells were dif-
ferentiated in vitro in the presence of G-CSF to measure re-
constitution of oxidase activity in mature granulocytes. The
percentage of superoxide-producing CD11b-positive cells
(29.7% – 10.7%) correlated well with the percentage of
gp91phox-expressing cells and corresponded to 40% of the
values detected in CD11b + cells derived from healthy
CD34 + cells (Fig. 1C). Transduced X-CGD CD34 + cells were
also injected in sublethally irradiated immunodeficient mice.
Gp91phox expression and superoxide production were esti-
mated 3 weeks after transplantation in the peripheral blood
of recipient mice and in vitro differentiated BM cells from
transplanted animals, respectively. Gp91phox expression was
found in 11.4% – 3.6% of the huCD45 + human peripheral
blood cells (Fig. 1D), whereas 9.1% of the cells were found
to produce superoxide after G-CSF-induced myeloid dif-
ferentiation and phorbol-12-myristate-13-acetate stimula-
tion (Fig. 1E). Notably, the mean levels of superoxide
production per cell were 60% of wt levels, as estimated from
the mean fluorescence intensity (MFI; Fig. 1E). These values
are therapeutically relevant and likely to be sufficient to
improve health conditions in CGD patients, as residual
superoxide production level is a predictor of survival in
CGD patients. Indeed, in a recent study comprising a total
of 287 CGD patients (67.9% X-CGD patients), a strong as-
sociation between long-term survival and residual super-
oxide production was observed (Kuhns et al., 2010).
According to this study, a survival benefit is expected for
CGD patients with as low as 1% of normal superoxide
production levels. From this analysis, we anticipate a sig-
nificant benefit for X-CGD patients receiving an autologous
transplant containing SINfes.gp91s gene-modified cells.
Decisive for the successful treatment of CGD patients is
the production of sufficient superoxide levels in transduced
cells to alleviate typical CGD symptoms. Aspergillus fumi-
gatus (AF) is an opportunistic fungal pathogen that can
cause serious infectious and inflammatory complications in
patients with CGD. As measures of therapeutic efficacy in
X-CGD animals that were transplanted with retrovirally
transduced syngeneic hematopoietic cells, we evaluated
whether these animals were protected from hyperin-
flammatory responses caused by the intradermal injection
of sterile AF hyphae (Petersen et al., 2002; Goebel et al., 2005)
and from pneumonia after respiratory challenge with live
AF conidia (Bjorgvinsdottir et al., 1997; Dinauer et al., 2001).
In these experiments, busulfan-conditioned CGD mice were
transplanted with SINfes.gp91s-transduced cells (see Sup-
plementary Materials and Methods). Oxidase activity in
peripheral blood polymorphonuclear leukocytes (PMNs)
(mostly neutrophils) was sustained during the first 10
months after transplantation and ranged between 12% and
48% with a MFI of about 1/10 of wt levels (Fig. 2A
and Supplementary Table S1). The mean VCN in donor-
derived cells obtained from the BM of selected animals (86–
90% chimerism) 7 months after transplantation was 0.17
vector copies per cell (range 0.12–0.22; Supplementary
Table S1), with oxidase activity ranging between 13% and
36% in the PMNs obtained from of these animals.
After intradermal challenge with sterile AF hyphae, X-
CGD mice develop a persistent inflammatory response that
is characterized by an acute infiltration of neutrophils at the
site of injection (1–3 days) followed by a chronic inflamma-
tory reaction 30 days postinjection because of infiltrating
neutrophils, mononuclear cells, and giant cells (Petersen
et al., 2002; Goebel et al., 2005). Seven months after trans-
plantation, eight animals were challenged by intradermal
injection of 2.5 lg sterilized AF hyphae into one ear, with the
contralateral ear injected with saline only. No significant
changes in oxidase activity were observed at this time point
compared with the initial values ( p> 0.05; Fig. 2A). Indeed,
PMNs of transplanted animals expressed substantial
amounts of glycosylated (91 kDa) and nonglycosylated
(64 kDa) gp91phox protein at this time point as demonstrated
in Western blots (Fig. 2B). The degree of inflammation was
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measured by the thickness of the ear at the site of injection 3
and 10 days after injection (Fig. 2C). While wt animals
showed a reduced inflammatory response at day 3, which
was not enhanced at day 10, X-CGD mice suffered from a
severe inflammatory response that was not controlled at day
10 postinjection. In contrast, most of the animals trans-
planted with SINfes.gp91s-transduced cells showed limited
inflammation at the site of injection, which decreased at day
10, demonstrating effective control of inflammation by gene-
modified cells. At 30 days postinjection, the mice were sac-
rificed and a 5mm punch biopsy was then taken from each
ear. Biopsy specimens were evaluated for the presence or
absence of inflammatory cells, and were graded on a 0–3+
scale, with a score of 0 indicating no inflammation (e.g., as
seen in ears injected with phosphate buffered saline), and a
score of 3 + denoting maximum inflammation as observed in
X-CGD controls. X-CGD mice ears showed a severe (grade
2–3+ ) inflammatory response, characterized by a massive
infiltration of neutrophils and macrophages (Fig. 2D). In
contrast, the ear challenge data showed that treated CGD
FIG. 1. Gp91phox expression and functional reconstitution of superoxide production by SINfes.gp91s-transduced cells
in vivo. Representative examples of gp91phox expression (A and B, upper panels) and superoxide production (A and B, lower
panels) in granulocytes of primary (A) and secondary (B) animals transplanted with SINfes.gp91s-transduced lin - cells.
Transgene expression analysis was performed 18 (primary) and 16 (secondary) weeks after transplantation. Intracellular
staining using a monoclonal antibody (7D5) was used to detect gp91phox expression. NADPH oxidase activity (A and B,
lower panels) was assessed in the same samples as above by the oxidative burst assay (DHR). The percentage of gp91phox
expressing Gr-1 + cells and superoxide production in CD11b + Gr-1 + donor cells as well as the MFI of rhodamine 123 is
shown. (C) Reconstitution of oxidase activity in the progeny of primary human CD34 + cells from X-CGD patients transduced
with SINfes.gp91s after in vitro differentiation. NADPH oxidase activity was measured in CD11b + cells by the DHR assay
after in vitro differentiation of nontransduced (X-CGD) or transduced cells. In vitro differentiated CD34 + cells from a healthy
donor served as positive control (WT). (D) Reconstitution of gp91phox expression in primary human hematopoietic cells
in vivo. X-CGD CD34+ cells were transduced with SINfes.gp91s or left untreated (X-CGD). About 107 cells were transplanted
into sublethally irradiated (2.5Gy) immunodeficient mice. Three weeks after transplantation, blood was obtained from the
tail vein of the animals and gp91phox expression was analyzed in human cells (huCD45) by fluorescence-activated cell sorting.
(E) Reconstitution of oxidase activity in vivo. Bone marrow cells obtained from NOD/scid/IL-2Rc null mice transplanted
either with nontransduced (X-CGD) or SINfes.gp91s-transduced X-CGD CD34+ cells or cells from a healthy donor (WT) were
differentiated ex vivo for 2 weeks in the presence of G-CSF. NADPH oxidase activity was measured after phorbol-12-
myristate-13-acetate stimulation in the huCD45 + cell fraction by the DHR assay. Cells were costained for CD11b expression.
The percentage of superoxide production in huCD45 + CD11b + cells and the MFI of rhodamine-123-positive cells are indi-
cated. DHR, dihydrorhodamine-123; MFI, mean fluorescence intensity; NADPH, nicotinamide dinucleotide phosphate; WT,
wild type; X-CGD, X-linked form of chronic granulomatous disease.
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mice had no severe suppuration (grade 3+) as observed in
untreated X-CGD mice, although many of the mice still had
some thickening. In the treated group, six mice showed
lymphocytic/histiocytic (macrophages) chronic infiltrates
graded 1–3 + , whereas three mice were found to have grade
1–2 + suppurative granulocytic infiltration.
As a second measure of therapeutic efficacy, CGD mice
transplanted with SINfes.gp91s-transduced marrow were
challenged with live AF conidia administered by intra-
tracheal instillation. In addition to wt and CGD controls, we
also studied mice that were mixed chimeras of wt and CGD
leukocytes, generated by transplanting lethally irradiated
mice with mixtures of wt and CGD marrow. Four to seven
months after transplantation, 200 conidia, a dose previously
shown to establish chronic pneumonia in 100% of CGD mice
(Dinauer et al., 2001), was instilled into the lungs. Fourteen
days later, mice were sacrificed and lung histology was
scored (Table 1). All X-CGD mice had multifocal granulomas
with microabscesses or diffuse inflammation, with scores
ranging from 1 to 4 (mean score 2.2). The wt mice had no
evidence of lung disease, as expected. Almost all of the WT/
X-CGD chimeric mice and SINfes.gp91S-transplanted mice
also had no evidence of lung disease, even for mice with as
few as 10–20% NADPH-oxidase-positive neutrophils. In the
one mouse in each of these categories that had detectable
lung disease, only small focal granulomas (with a score of 1)
were detected. Thus, the SINfes.gp91s vector was able to
protect animals from AF-induced inflammatory reactions
FIG. 2. Suppression of hyperinflammatory response in X-CGD mice transplanted with SINfes.gp91s-transduced cells. (A)
Oxidase activity in peripheral blood PMNs over time after transplantation of either 1 · 106 (solid bars) or 2· 106 (open bars)
SINfes.gp91s-transduced lin - cells into X-CGD animals. Mean values – SEM are given. p-Values according to two-tailed t-
test. (B) Human gp91phox expression in peripheral blood PMNs of animals transplanted with SINfes.gp91s-transduced cells.
PMNs were obtained from the indicated animals 7 months after transplantation. Gp91phox was detected by Western blotting
using the CL5 antibody (Sadat et al., 2009). Cell extracts from human PMN were used at different concentrations as control.
No cross-reaction with murine gp91phox was observed as indicated by the lack of hybridization in cell extracts obtained from
wild-type mice (WT). The percentage of oxidase-positive cells is indicated below. (C and D) X-CGD animals transplanted
with SINfes.gp91s-transduced cells are protected from Aspergillus fumigatus (AF) challenge. Seven months after transplan-
tation, sterile AF hyphae were injected intradermally into one of the ears of the animals. As a control, saline was injected into
the contra lateral ear. The degree of inflammation at the AF injection site was estimated at 3 and 10 days after injection from
the ear thickness at the injection site (C) or the weight of a 5mm ear punch biopsy taken 30 days after injection (D). Black bars,
AF injection; white bars, saline injection. Values between 1 and 3 denote the severity of the inflammation, with 1 being low
and 3 high. LH, lymphocytic/histiocytic (macrophages) infiltration; NL, normal; PMNs, polymorphonuclear leukocytes;
SEM, standard error of the mean; SG, suppurative/granulomatous.
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and gave CGD mice a high degree of protection from
pneumonia induced by AF at very low VCNs. In addition,
our analysis indicates that both expression of gp91phox and
NADPH oxidase activity were sustained for 7 months in vivo.
The c-FES promoter is less prone to CpG methylation
in hematopoietic cells
As transcriptional silencing of transgene expression was
one of the unwanted effects observed in our previous phase I
clinical trial conducted with the SF71gp91phox vector (Ott
et al., 2006; Stein et al., 2010), we investigated the level of CpG
methylation at the c-FES promoter in SINfes.gp91s-trans-
duced hematopoietic cells. BM cells obtained from trans-
planted animals (low-VCN group) at week 30 were plated in
methylcellulose and tested for the presence of vector se-
quences by PCR and superoxide production by the nitroblue
tetrazolium assay. Superoxide production was detected in
38% of the colonies (WT 55.7%), which is similar to the
percentage of superoxide-positive granulocytes detected in
peripheral blood of these animals (20–40%, Supplementary
Fig. S2C). Isolated vector-positive BM colonies but negative
for superoxide production were tested for CpG methylation
at the c-FES promoter by bisulfite sequencing. Only sporadic
CpG methylation was detected within the fes promoter in the
samples analyzed (Fig. 3A), suggesting that the lack of su-
peroxide activity was not caused by inactivation of the c-FES
promoter by methylation, but rather by chromosomal posi-
tional effects or by partial myeloid differentiation of BM
colonies. Alternatively, codon optimization may favor CpG
methylation because of increased GC content. Indeed Di et al.
(2012) have shown that codon optimization may lead to CpG
methylation and transgene silencing. However, this phe-
nomenon was only seen when the spleen focus-forming virus
(SFFV) promoter was placed in front of the codon-optimized
transgene. The inclusion of a cellular promoter with low CpG
content did not lead to CpG methylation of the transgene or
to transgene silencing (Di et al., 2012). Therefore, the most
plausible explanation for the lack of gp91phox expression in
BM-derived colonies is position effect or partial myeloid
differentiation. To confirm these results, a more stringent
methylation assay using the murine embryonic carcinoma
cell line P19 was performed. Methylation-dependent re-
pression of gene expression in P19 cells occurs shortly after
DNA transfer into the cells and recapitulates the usually
slow process of promoter silencing observed in somatic cells.
Thus, P19 cells provide a sensitive system to test DNA
methylation-dependent inactivation of gene expression. We
transduced P19 cells with the SINfes.gp91s vector. As a
control we used the SF71gp91phox vector, in which gp91phox
expression is under the transcriptional control of the SFFV
LTR. DNA was extracted from transduced cells at different
time points and analyzed for CpG methylation by bisulfite
modification followed by sequencing. As expected, a rapid
methylation at CpG dinucleotides occurred within the SFFV
enhancer/promoter, with more than 80% of the CpG sites
methylated already at day 9 post-transduction. In contrast,
the c-FES promoter was at least three- to sixfold less sensitive
to CpG methylation than the SFFV promoter, with 60% of the
CpGs remaining unmethylated even at day 20 after trans-
duction, a time point at which the SFFV LTR was almost
fully methylated (Fig. 3B and C). These results suggest that
the c-FES promoter is less prone to methylation-mediated
silencing during hematopoiesis and is capable of maintaining
therapeutic gene expression even in an unfavorable envi-
ronment. This observation correlates well with the long-term
and stable reconstitution of superoxide activity observed in
transplanted CGD animals (Fig. 2).
SINfes.gp91s exhibits a low genotoxic potential
in vitro and in vivo
Former clinical gene therapy trials using LTR-driven vec-
tors for modification of hematopoietic stem cells have shown
that genotoxicity and subsequent development of hemato-
logical malignancies can be a major threat for the patients.
Therefore, an essential component of preclinical assessment
of new vectors is toxicology, including evaluation of geno-
toxicity in vitro and in vivo. Initially, we used the in vitro
immortalization (IVIM) assay to estimate vector genotoxi-
city, as this assay relies on the induction of a survival ad-
vantage by insertional activation of cellular proto-oncogenes,
which becomes apparent when primary murine hematopoi-
etic cells are cultured under differentiating cytokine condi-
tions and plated in limiting dilution (Modlich et al., 2006).
This assay is frequently being used as a surrogate assay for
in vivo experiments as it faithfully predicts malignant events,
which may occur in gene therapy trials, at least those af-
fecting the myeloid compartment (Baum et al., 2011).
Therefore, genotoxicity of SINfes.gp91s was first investigated
in the IVIM assay, using the LTR-driven SF71gp91phox and
the SIN vector SINSF.eGFP vector as positive controls to
validate the assay (Modlich et al., 2006). In parallel, we tested
a SINSF.gp91s vector as well as a vector containing a cata-
lytic inactive mutant of gp91phox (gp91s-P415H) (Dinauer
et al., 1989) to exclude any potential toxicity of gp91phox that
Table 1. Pulmonary Disease in Mice After
Challenge with Aspergillus fumigatus
Group n
% Oxidase-
positive PMNs
A. fumigatus
lung disease
WT mice 8 > 95 0/8
X-CGD mice 9 0 9/9
WT/X-CGD transplantation
chimeras
4 13–15 1/4
5 32–54 0/5
SINfes.gp91S-transplanted
X-CGD mice
4 10–19 1/4
3 26–29 0/3
4 34–37 0/4
Oxidase-positive PMNs were determined by dihydrorhodamine-
123 assay before intratracheal challenge with 200 A. fumigatus
conidia. Mice were sacrificed 14 days after challenge. Lung histology
was scored in a blinded manner, following a scoring system
correlating with histopathologic severity. Three cross sections were
scored in three categories: focal granulomas and/or microabscesses,
multifocal granulomas and/or microabscesses, or diffuse inflam-
mation covering the lung lobe. All X-CGD mice had multifocal
granulomas with microabscesses or diffuse inflammation, with
scores ranging from 1 to 4 (mean score 2.2). The WT/X-CGD
chimera and SINfes.gp91S-transplanted mice with detectable lung
disease had small focal granulomas only. PMNs, polymorphonuclear
leukocytes; WT, wild type; X-CGD, X-linked form of chronic
granulomatous disease.
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could have affected the readout of the assay. Lastly, in most
experiments we used murine lineage negative (lin - ) cells
obtained from X-CGD animals to preserve a disease-specific
cell background. No differences in the frequency of immor-
talized clones were found neither when lin - cells derived
from C57Bl/6 or X-CGD animals, nor when gp91phox or its
catalytic inactive mutant were used (Fig. 4). In line with
previous studies of SIN vectors (Modlich et al., 2006), SIN-
fes.gp91s displayed a significantly lower frequency of im-
mortalization compared with its LTR-driven counterpart
(Fig. 4). The mean replating frequency observed with the
SINfes.gp91s vector was 3.13E-05 – 0.198E-05 (n= 13), a value
46.6-fold lower than that observed with the SINSF.eGFP
vector and 22-fold lower than that of SF71gp91phox, the
vector used in our previous clinical trial (Fig. 4). Besides
providing a quantitative estimation on the incidence of ma-
lignant transformation, the IVIM assay also allows to esti-
mate the fitness of transformed cells, which is calculated
from the replating frequency of transformed cells as a func-
tion of vector dose and vector design (Modlich et al., 2006,
2009; Zychlinski et al., 2008). The SINfes.gp91s vector was
tested 10 times in gp91phox knockout cells in five indepen-
dent assays and 3 times in wt cells (Supplementary Table S2).
In two assays, one clone with replating capacity could be
recovered; all others gave negative results. In eight assays,
the LTR-driven SF71gp91phox vector was tested side by side
and gave rise to numerous clones in all assays. Therefore, the
incidence of replating clones was significantly lower for the
SINfes.gp91s vector ( p= 0.0002; Fisher’s exact test). More-
over, the two clones arising from SINfes.gp91s-transduced
cells grew poorly in vitro and could not be expanded to mass
cultures for extensive molecular analysis, which is an indi-
cation for low fitness of these clones. Despite this, we at-
tempted to determine the genomic vector location in these
FIG. 3. The c-FES promoter is less prone to CpG methylation in hematopoietic cells. (A) Assessment of CpG methylation at
the c-FES promoter in CFC. DNA was extracted from individual vector-positive but oxidase-negative colonies derived from
the BM of transplanted X-CGD mice 30 weeks after transplantation and subjected to bisulfite conversion and sequencing. (B)
The c-FES promoter is less sensitive than the SFFV promoter to CpG methylation. P19 cells were transduced with
SF71gp91phox or SINfes.gp91s. DNA was extracted at different time points and analyzed for CpG methylation by bisulfite
sequencing. (C) Schematic diagram summarizing the data presented in (B). Mean values – SEM are shown. BM, bone
marrow; CFC, colony-forming cells; SFFV, spleen focus forming virus.
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clones by ligation-mediated PCR. A single integration site
(IS) was detected for each clone. None of these could be
assigned to Evi1 or Prdm16, the most common events usually
found in this assay (Modlich et al., 2009). The IS in one clone
mapped 790 bp upstream of the vinculin gene on chromo-
some 14 in forward orientation. Unfortunately, the sequence
retrieved from the second clone was too short (16 bp) for a
definite alignment on the mouse genome.
Finally, we determined the genotoxic potential of the
SINfes.gp91s vector in a long-term in vivo study. Primary
lin - murine BM cells isolated from male/female C57BL/6
X-CGD (CD45.2) mice were transduced with SINfes.gp91s at
a total multiplicity of infection (MOI) of 6.6 and with the
control vector SF91eGFP at an MOI of 5.2 to ensure high
VCNs per cell, thus enhancing the probability of insertional
mutagenesis. The LTR-driven SF91eGFP vector was chosen
as a positive control for assay validation, as this vector is
known to induce clonal dominance and leukemia in vivo
(Modlich et al., 2008, 2009). Transduction efficiency on lin -
cells was measured on day 10 by qPCR on vector sequences.
A mean VCN of 2.8 per cell was determined for SIN-
fes.gp91s-transduced cells, whereas this value was 1.6 vector
copies per cell for SF91eGFP-transduced cells. After trans-
duction, cells were expanded in a serum-free medium sup-
plemented with a cytokine cocktail previously shown to
expand long-term repopulating cells (Zhang et al., 2006).
Expanded cells were transplanted into lethally irradiated
recipients (C57BL/6 CD45.1) together with 100.000 fresh
BM-derived mononuclear cells (CD45.1) to ensure efficient
repopulation of transplanted animals. Animals were moni-
tored for a total of 30 and 16 weeks for primary and sec-
ondary transplanted recipients, respectively, resulting in a
total observation time of 11 months (Supplementary Fig. S3).
Engraftment of donor X-CGD CD45.2 cells into CD45.1
animals was assessed by fluorescence-activated cell sorting.
Nearly all animals were reconstituted to levels above 90%
with donor cells. VCNs were determined in DNA samples
obtained from peripheral blood, BM, and spleen of trans-
planted animals with mean values ranging between 2.5 and
3.4 in primary and between 2.6 and 3.7 in secondary animals
for SF91eGFP- and SINfes.gp91s-transduced cells, respec-
tively (Fig. 5A and B). Despite high engraftment and VCN in
BM, spleen, and peripheral blood, no vector-related malig-
nant abnormalities in hematologic organs were observed in
primary or secondary transplanted animals at any time
point. The percentage of lymphocytes (*70%), monocytes
(*10%), and granulocytes (*20–25%) in the peripheral blood
of the SINfes.gp91s animals were not different from those
observed in control C57BL/6 animals. Similarly, the body
weight of animals in the test group remained constant in a
range between 20 and 30 g, and was thus not different from
the control groups. Occasionally, we found CGD-related
FIG. 4. Frequency of immortalization of lin - cells by SINfes.gp91s in vitro. (A) lin - cells from X-CGD mice were trans-
duced on two consecutive days at an MOI of 10 per day with different gp91phox or eGFP coding vectors, expanded in bulk for
14 days as described in the Supplementary Materials and Methods and plated at a density of 100 cells per well in 96-well
plates. After 14 days, plates were screened for colony growth, and the frequency of replating was calculated based on Poisson
statistics using L-Calc software. The graphic shows the frequency of replating cells corrected for the average vector copy
number as measured by quantitative PCR on day 4 after transduction. The limit of detection of the assay is indicated as a
thick black line. The dotted line reflects the immortalization frequency of RSF91.eGFPpre*, an LTR-driven gammaretroviral
vector expressing eGFP. (B) Schematic diagram of the vectors used in this study. lin- , lineage negative; LTR, long terminal
repeat; MOI, multiplicity of infection; PCR, polymerase chain reaction.
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symptoms, such as granulomas, in the lungs of animals
transplanted with SF91eGFP-transduced X-CGD cells.
Because of the lack of overt malignancies in transplanted
animals, we decided to perform a clonal distribution analysis
by ligation-mediated/linear-amplification-mediated PCR in
combination with deep sequencing. The identification of
unique vector integration site (IS) as molecular markers
for each individual cell and its clonal progeny provides in-
formation on clonal dynamics, degree of in vivo clonal
skewing, and frequency of targeting worrisome genomic
regions, that is, proto-oncogenes, and allows the assessment
of the genotoxic potential of the vectors used (Schmidt et al.,
2007). We randomly selected four SF91eGFP and five SIN-
fes.gp91s primary animals and their respective progeny for
this analysis.
We found a mean of 482 and 714 unique IS per mice in
primary SF91eGFP and SINfes.gp91s animals, respectively
(Fig. 5C and Supplementary Fig. S4). A remarkably high
retrieval frequency of IS sequence reads for particular genes
targeted repeatedly by the SF91eGFP vector was evident in
most primary animals, with Hoxa6 (15% retrieval frequency
in M#4), Evi1 (31% retrieval frequency in M#5), and Ccdc60
(15–17% retrieval frequency in M#6) being among the most
prominent integrations found (Fig. 6 and Supplementary
Fig. S4). In contrast, in SINfes.gp91s-transplanted animals,
we did not detect multiple independent vector integrations
(> 4) in the same genomic region (common insertion sites)
with an increased retrieval frequency above 10%. Only 4
clones containing single integrations into Il1rl2 (10.1%),
D4Wsu53e (10.7%), Tyrobp (11%), or Rmnd5b (15%) showed
retrieval frequencies above 10%, the threshold arbitrarily set
for defining dominant clones. Notably, measuring clonal
contributions using the retrieval frequency of individual IS
sequences gives an estimate on the presence of the respective
cell clone(s) in the analyzed tissue/cell fraction and allows a
reliable longitudinal monitoring of these clones over time,
although the method used here does not allow a precise
determination of clone size in a mixed population.
Three of the predominant clones found in SINfes.gp91s
primary animals (Tyrobp, Rmnd5b, and D4Wsu53e) were
found in secondary animals, but with declining clonal con-
tributions, most likely because of the lack of repopulating
FIG. 5. Vector copy numbers and total number of ISs per mouse in SINfes.gp91s- and SF91eGFP-transplanted animals.
Vector copy numbers in DNA samples obtained from PB, BM, and SP of transplanted primary (A) and secondary (B) animals.
(C) Total number of ISs per mouse. ISs were obtained from serially transplanted SF91eGFP and SINfes.gp91s mice by
ligation-mediated/linear-amplification-mediated PCR and subsequent 454 sequencing. (D) Percentage of ISs found in or
close to the Mds1/Evi1 locus for primary and secondary transplanted mice. With SINfes.gp91s, significantly less ISs were
detected in primary and in secondary animals, respectively. *p = 0.077 and 0.026 for primary and secondary mice, respec-
tively, as determined by v2-test. BM, bone marrow; ISs, integration sites; PB, peripheral blood; SP, spleen.
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capabilities of these particular clones (Supplementary Fig.
S4). Similarly, the dominant Evi1 clone detected in the BM of
SF91eGFP mouse M#5 was barely detectable in secondary
animals, with a clonal contribution of less than 0.04% (Sup-
plementary Table S1). In contrast, the predominant Hoxa6
clone was found at a retrieval frequency of 19.3% and 55.8%
in animals transplanted with BM cells derived from M#4,
indicating a dominant clone with engraftment potential (Fig.
6). Further predominant clones in secondary animals trans-
planted with SF91eGFP-transduced cells contained integra-
tions into Glrx3 (retrieval frequency 52%), Pdcd1lg2 (42%),
1700019N12Rik (36%), Capn5 (34%), and Prkar2b (30%) (Fig.
6). All of these clones were also detected in the correspond-
ing primary animals. On the basis of the sequence reads,
however, the contribution to gene marked hematopoiesis
was below 5%. Most likely, clonal dominance correlated with
increased transcription at the targeted locus, as we detected
increased transcription levels for Evi1, Hoxa6, and Glrx3 in
primary and secondary animals, respectively (Supplemen-
tary Fig. S5).
Three clones with clonal contributions slightly above the
threshold of 10% were found in secondary SINfes.gp91s
animals (Map3k7ip2, 10.7%; Mamdc2, 10.9%; B4galt5, 12.2%).
However, two of these were not detected in a second recip-
ient of the same BM cells (Mamdc2) or its contribution was
well below the threshold of 10% (B4galt5). For the third one
(Map3k7ip2), we had only one secondary mouse, as the sec-
ond animal transplanted with the same BM cells died at
week two post-transplantation because of engraftment fail-
ure. One clone with a dominance above 20% was observed in
an animal (P7#41) transplanted with a pool of BM cells ob-
tained from M#29 and M#30 (Fig. 6). This particular clone
contained a proviral integration upstream of the Cnot6I gene
(CCR4-NOT transcription complex; NM_144910) and was
found at a frequency of 22.3%. However, attempts to detect
increased transcripts in BM cells from this animal failed
(Supplementary Fig. S5). Indeed, the transcription levels for
Cnot6I in P7#41 were not significantly different from those
found in animal P7#42 ( p > 0.05), in which the contribution of
the Cnot6I clone to total gene marked hematopoiesis was less
than 7% (Supplementary Fig. S4). This is reminiscent of a
previous study in which clonal dominance was observed
upon transplantation of hematopoietic cells transduced
with a SIN vector lacking an internal enhancer–promoter
FIG. 6. Retrieval frequency of individual ISs in SINfes.gp91s- and SF91eGFP-transplanted animals. Retrieval frequency of
individual sequences in PB, BM, and SP of SF91eGFP- and SINfes.gp91s-transplanted primary (upper diagram) and sec-
ondary animals (lower diagram) at different time points after transplantation. DNA was extracted from the indicated
samples, and retroviral vector integrations sites were retrieved by ligation-mediated/linear-amplification-mediated PCR and
subsequent 454 high-throughput sequencing. The relative sequence count gives a semiquantitative estimation for the con-
tribution of clones carrying a unique IS to total gene-marked hematopoiesis. A threshold of 10% was arbitrarily set to define a
significant contribution of a clone to hematopoiesis. All ISs with a sequence retrieval frequency above 10% are marked.
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sequence, suggesting that clonal restriction is a physiological
phenomenon in this transplantation setting (Cornils et al.,
2009, 2012).
In view of the relevance of integrations into or close to
the Mds1/Evi1 locus, we analyzed the frequency of inte-
grations at this locus in SINfes.gp91s- and SF91eGFP-
transplanted animals independently of their contribution to
gene-marked hematopoiesis. From a total of 1759 (primary
mice)/418 (secondary mice) and 3324 (primary mice)/836
(secondary mice) unique IS for SF91eGFP and SINfes.gp91s,
respectively, the percentage of IS that were identified in or
close to the Mds1/Evi1 locus in primary and secondary an-
imals was significantly less in SINfes.gp91s- than in
SF91eGFP-transplanted animals ( p = 0.077 and 0.026, re-
spectively, determined by v2-test) (Fig. 5D). On the basis of
this observation, the risk of insertional activation of Evi1 by
the SINfes.gp91s vector is substantially reduced compared
with SF91eGFP.
In addition, we applied the Shannon and the Simpson
diversity indexes for a more precise assessment of the het-
erogeneity of hematopoietic repopulation in the treated ani-
mals. The Shannon index is used to determine the number of
unique repopulating clones (richness of a population),
whereas the Simpson index measures the degree of clonal
dominance with a high index indicating low clonal domi-
nance (Shannon, 1948; Simpson, 1949). We observed that in
both cohorts the average indices were substantially increased
for SINfes.gp91s-treated animals compared with the SF91
controls (Supplementary Fig. S6), thus confirming the re-
duced probability of this vector to affect the transduced cell
and to cause unwanted clonal outgrowth. These data, to-
gether with the low frequency of in vitro immortalized clones
found in SINfes.gp91s-transduced lin - cells, even at >15
vector copies per cell (Fig. 4), demonstrate a low genotoxicity
profile for this vector and reinforce the relevance of vector
design for the safety of future clinical studies (Modlich et al.,
2006; Montini et al., 2009; Schambach et al., 2009). In addition,
our studies support the use of clonal dominance as a surro-
gate assay to define the genotoxicity profile of integrating
vectors. The use of new technologies, that is, barcoding, to
mark gene-transduced cells (Gerrits et al., 2010; Glimm et al.,
2011; Lu et al., 2011) will certainly facilitate the analysis of
clonal dominance in the future.
Conclusions
Gene therapy has proven to be effective in correcting X-
CGD, at least temporarily. A series of phaseI/II studies using
a variety of different gammaretroviral vectors have shown
partial correction of the disease shortly after reinfusion of
gene-transduced cells [reviewed in (Grez et al., 2011)].
However, long-term correction of the disease failed in most
cases. Probably, the low-intensity conditioning used in these
trials accounts for treatment failure, as in the absence of
in vivo selection autologous transplantation of either gam-
maretrovirus- or lentivirus-transduced hematopoietic stem
cells in nonhuman primates treated with nonmyeloablative
regimens have generally resulted in low levels (1% or less) of
long-term marking (Huhn et al., 1999; Rosenzweig et al., 1999;
Brenner et al., 2006; Kahl et al., 2006; Kang et al., 2006). Thus,
for future trials, intensified conditioning may be necessary,
as gene-corrected cells are not expected to have a selection
advantage in CGD. However, the application of LTR-driven
vectors, as used in previous trials, would pose a serious
safety concern under these conditions as more stem and
primitive progenitor cells are supposed to engraft after
myeloablative conditioning. These considerations prompted
us to develop an optimized SIN gammaretrovirus-based
vector (SINfes.gp91s) for the clinical application in X-CGD.
The SINfes.gp91s vector restores superoxide production in
X-CGD cells to therapeutically relevant levels even at low
VCNs and has a significantly improved genotoxicity profile
without signs of transformation in genotoxicity assays,
making this vector a promising candidate for safe future
clinical application. Indeed, a stable packaging cell line for
vector production was established and clinical vector
lots have been produced (Loew et al., 2010). Moreover, the
SINfes.gp91s vector was recently approved for the modifi-
cation of human hematopoietic cells in the context of a
clinical phase I/II study (Paul Ehrlich Institute reference
number A.11492.01.1).
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